WASHINGTON, July 24 (Reuters) - U.S. regulators are concerned that a proposed King Pharmaceuticals Inc (KG.N) imaging agent may produce inferior results compared with a commonly used agent, documents released on Friday said.
WASHINGTON, July 24 (Reuters) - U.S. regulators are concerned that a proposed King Pharmaceuticals Inc (KG.N) imaging agent may produce inferior results compared with a commonly used agent, documents released on Friday said.
